BioSpecifics Technologies Corporation

35 Wilbur Street
Lynbrook
New York
11563-2358
United States

Tel: 516-593-7000
Fax: 516-593-7010

Show jobs for this employer

219 articles with BioSpecifics Technologies Corporation

  •  BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the successful completion of its acquisition by Endo International plc (End

  • Endo International plc announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the previously announced tender offer by Beta Acquisition Corp...

  • BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, announced its financial results for the third quarter ended September 30, 2020.

  • Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating BioSpecifics Technologies Corp. ("BioSpecifics" or the "Company") ( BSTC ) relating to its proposed acquisition by Endo International PLC. Unde

  • - Endo International plc (NASDAQ: ENDP) today announced it has agreed to acquire all of the outstanding shares of BioSpecifics Technologies Corp. (NASDAQ: BSTC), a commercial-stage biopharmaceutical company, for $88.50 in cash per share, or an estimated enterprise

  •  BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has entered into a definitive merger agreement under which Endo International plc (NASDAQ: ENDP) will acquire BioSpecifics for an estimated

  •  BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced that Joseph Truitt , Chief Executive Officer, will present at the virtual O

  •  BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced that Joseph Truitt , Chief Executive Officer, will present at the H

  • - Highly experienced business development executive, Alex Monteith, named as Senior Vice President and Chief Business Officer - Qwo™ (collagenase clostridium histolyticum-aaes) approved by FDA for treatment of cellulite - Patient dosing initiated in clinical trials for XIAFLEX® in both plantar fibromatosis and adhesive capsulitis

  • BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the appointment of Alex Monteith as Senior Vice President and Ch

  • It’s a relatively slow month ahead for July in terms of PDUFA dates for the U.S. FDA. However, there are several dates pending throughout the month. Here’s a look at three for the next two weeks.
  • Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers.
  • - 19% year-over-year increase in royalty revenues for XIAFLEX® - Highly experienced biopharma executive, Joseph Truitt, named as Chief Executive Officer and Mike Sherman and Corey Fishman appointed to Board of Directors - Initiation of CCH studies for plantar fibromatosis and adhesive capsulitis in 2H20   [11-May-2020]   WILIMINGTON, Del., May 11, 2020

  • BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America , today announced the appointment of Joseph Truitt as Chief Executive Officer. Mr. Truitt was appoint

  • BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced that its Board of Directors appointed Mike Sherman and Corey Fishman to serve as Independent Directors, effective immediately.

  • BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer.

  • BioSpecifics Technologies Corp. announced its financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.

  • BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced its financial results for the third quarter ended September 30, 2019 and provided a corporate update.

  • BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today named life sciences industry veteran Kevin Buchi chief executive officer of BioSpecifics

  •  BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2019 and provided a corporate update.